IL100731A - Mixed specificity fusion protein and pharmaceutical composition containing it - Google Patents
Mixed specificity fusion protein and pharmaceutical composition containing itInfo
- Publication number
- IL100731A IL100731A IL100731A IL10073192A IL100731A IL 100731 A IL100731 A IL 100731A IL 100731 A IL100731 A IL 100731A IL 10073192 A IL10073192 A IL 10073192A IL 100731 A IL100731 A IL 100731A
- Authority
- IL
- Israel
- Prior art keywords
- fusion protein
- pharmaceutical composition
- composition containing
- mixed specificity
- specificity fusion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70542—CD106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- C07K14/70564—Selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/645,522 US5709859A (en) | 1991-01-24 | 1991-01-24 | Mixed specificity fusion proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
IL100731A0 IL100731A0 (en) | 1992-09-06 |
IL100731A true IL100731A (en) | 1997-07-13 |
Family
ID=24589356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL100731A IL100731A (en) | 1991-01-24 | 1992-01-22 | Mixed specificity fusion protein and pharmaceutical composition containing it |
Country Status (18)
Country | Link |
---|---|
US (1) | US5709859A (no) |
EP (1) | EP0568645B1 (no) |
JP (1) | JP3394534B2 (no) |
KR (1) | KR100259061B1 (no) |
AT (1) | ATE195254T1 (no) |
AU (1) | AU648398B2 (no) |
CA (1) | CA2099779C (no) |
DE (1) | DE69231333T2 (no) |
DK (1) | DK0568645T3 (no) |
ES (1) | ES2148173T3 (no) |
FI (1) | FI109203B (no) |
GR (1) | GR3034524T3 (no) |
IE (1) | IE920202A1 (no) |
IL (1) | IL100731A (no) |
NO (1) | NO313241B1 (no) |
NZ (1) | NZ241357A (no) |
WO (1) | WO1992012994A1 (no) |
ZA (1) | ZA92467B (no) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6130202A (en) * | 1990-07-20 | 2000-10-10 | Bayer Corporation | Antiviral methods |
US6107461A (en) * | 1990-07-20 | 2000-08-22 | Bayer Corporation | Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use |
US5827670A (en) * | 1990-08-02 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies |
US7449186B1 (en) | 1990-08-02 | 2008-11-11 | Fred Hutchinson Cancer Research Center | Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies |
US5643873A (en) * | 1992-05-06 | 1997-07-01 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1 |
US5648458A (en) * | 1992-05-06 | 1997-07-15 | Affymax Technologies N.V. | Peptides and compounds that bind to ELAM-1 |
US5728802A (en) * | 1992-05-06 | 1998-03-17 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1) |
WO1994017193A2 (en) * | 1993-01-25 | 1994-08-04 | Dana-Farber Cancer Institute, Inc. | Chimeric l- and p-selectin by exchange of domains - uses thereof |
US6991790B1 (en) * | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
AU763719B2 (en) | 1997-12-08 | 2003-07-31 | Merck Patent Gmbh | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
AU3193399A (en) | 1998-03-23 | 1999-10-18 | Genentech Inc. | Method of selection for genes encoding secreted and transmembrane proteins |
CA2328076C (en) * | 1998-04-15 | 2009-10-06 | Lexigen Pharmaceuticals Corporation | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
WO2000058501A2 (en) * | 1999-03-26 | 2000-10-05 | The Wistar Institute | Novel genetic suppressor elements and methods of making the same |
CZ20014123A3 (cs) * | 1999-05-19 | 2002-06-12 | Lexigen Pharmaceuticals Corp. | Exprese a export interferonů-alfa jako Fc fúzních proteinů |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US7067110B1 (en) * | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
CA2380331C (en) * | 1999-08-09 | 2012-11-20 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
GB9929151D0 (en) * | 1999-12-09 | 2000-02-02 | Univ Cambridge Tech | Peptide and polypeptide display |
CA2399832C (en) | 2000-02-11 | 2011-09-20 | Stephen D. Gillies | Enhancing the circulating half-life of antibody-based fusion proteins |
WO2001089564A2 (en) * | 2000-05-19 | 2001-11-29 | The Center For Blood Research, Inc. | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
AU2001271729B2 (en) * | 2000-06-29 | 2007-01-04 | Merck Patent Gmbh | Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
KR20090010127A (ko) * | 2001-03-07 | 2009-01-28 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술 |
WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
DE60239454D1 (de) | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | Rekombinanter, tumorspezifischer antikörper und dessen verwendung |
CA2447583A1 (en) * | 2001-05-16 | 2003-03-27 | Ceptyr, Inc. | Dsp-18 dual-specificity phosphatase |
US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
PT1454138E (pt) * | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
US20030219436A1 (en) * | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
RU2366664C2 (ru) * | 2002-12-17 | 2009-09-10 | Мерк Патент Гмбх | Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2 |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
EP1699822B1 (en) * | 2003-12-30 | 2008-04-23 | MERCK PATENT GmbH | Il-7 fusion proteins with antibody portions, their preparation and their use |
BRPI0417916A (pt) * | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
EP1702069A2 (en) * | 2004-01-05 | 2006-09-20 | EMD Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
US8298532B2 (en) | 2004-01-16 | 2012-10-30 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
UY28886A1 (es) | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18 |
RU2412945C2 (ru) * | 2004-05-11 | 2011-02-27 | Эбдженомикс Кооператиф У.А. | Эпитопы, индуцирующие гибель т-клеток |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
BRPI0519000A2 (pt) * | 2004-12-09 | 2008-12-23 | Merck Patent Gmbh | variantes de il-7 com imunogenicidade reduzida |
HUE026303T2 (hu) * | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
EP2418223A3 (en) * | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
DK2132228T3 (da) | 2008-04-11 | 2011-10-10 | Emergent Product Dev Seattle | CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf |
JP5781501B2 (ja) * | 2009-04-22 | 2015-09-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 改変されたFcRn結合部位を有する抗体融合タンパク質 |
KR101632312B1 (ko) * | 2009-11-03 | 2016-06-21 | 삼성전자주식회사 | 항체 불변 영역에 특이적으로 결합하는 융합 단백질, 그의 제조 방법 및 이를 이용한 항체 분리 방법 |
WO2011103164A1 (en) | 2010-02-18 | 2011-08-25 | Centocor Ortho Biotech Inc. | Monkey homolog of human interferon omega |
EP2558482B1 (en) | 2010-04-16 | 2017-09-27 | Janssen Biotech, Inc. | Engineered plant cysteine proteases and their uses |
EP2621950A4 (en) | 2010-09-27 | 2015-09-02 | Janssen Biotech Inc | ANTIBODIES FOR BINDING HUMAN COLLAGEN II |
SG10201407036YA (en) | 2010-11-05 | 2014-12-30 | Transbio Ltd | Markers of Endothelial Progenitor Cells and Uses Thereof |
KR102103036B1 (ko) | 2011-06-13 | 2020-04-22 | 압제노믹스 코오페라티에프 유.에이. | 항-psgl-1 항체 및 그의 용도 |
CN108367004B (zh) | 2015-09-21 | 2022-09-13 | 阿帕特夫研究和发展有限公司 | Cd3结合多肽 |
TW201732037A (zh) * | 2015-10-15 | 2017-09-16 | 安瑟吉納西斯公司 | 自然殺手細胞及ilc3細胞及其用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5109123A (en) * | 1988-06-14 | 1992-04-28 | Dana Farber Cancer Institute | Alteration of ability of soluble CD4 fragments to bind HIV |
US5147637A (en) * | 1988-06-07 | 1992-09-15 | The Rockefeller University | Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma |
EP0365837B1 (en) * | 1988-09-28 | 1995-08-02 | Dana Farber Cancer Institute | Intercellular adhesion molecules, and their binding ligands |
US5272263A (en) * | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
EP0585963A1 (en) * | 1989-05-23 | 1994-03-09 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies to CMP-170 antigen on activated endothelial cells |
US6458360B1 (en) * | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
-
1991
- 1991-01-24 US US07/645,522 patent/US5709859A/en not_active Expired - Lifetime
-
1992
- 1992-01-22 IL IL100731A patent/IL100731A/xx not_active IP Right Cessation
- 1992-01-22 NZ NZ241357A patent/NZ241357A/en not_active IP Right Cessation
- 1992-01-23 IE IE020292A patent/IE920202A1/en not_active IP Right Cessation
- 1992-01-23 ZA ZA92467A patent/ZA92467B/xx unknown
- 1992-01-24 JP JP50624792A patent/JP3394534B2/ja not_active Expired - Lifetime
- 1992-01-24 DE DE69231333T patent/DE69231333T2/de not_active Expired - Lifetime
- 1992-01-24 EP EP92906135A patent/EP0568645B1/en not_active Expired - Lifetime
- 1992-01-24 ES ES92906135T patent/ES2148173T3/es not_active Expired - Lifetime
- 1992-01-24 DK DK92906135T patent/DK0568645T3/da active
- 1992-01-24 AT AT92906135T patent/ATE195254T1/de not_active IP Right Cessation
- 1992-01-24 KR KR1019930702204A patent/KR100259061B1/ko not_active IP Right Cessation
- 1992-01-24 WO PCT/US1992/000616 patent/WO1992012994A1/en active IP Right Grant
- 1992-01-24 CA CA002099779A patent/CA2099779C/en not_active Expired - Lifetime
- 1992-01-24 AU AU13391/92A patent/AU648398B2/en not_active Expired
-
1993
- 1993-07-05 NO NO19932437A patent/NO313241B1/no not_active IP Right Cessation
- 1993-07-21 FI FI933292A patent/FI109203B/fi active
-
2000
- 2000-09-29 GR GR20000402214T patent/GR3034524T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
ZA92467B (en) | 1992-09-30 |
NO932437L (no) | 1993-09-17 |
JPH06505388A (ja) | 1994-06-23 |
FI109203B (fi) | 2002-06-14 |
DK0568645T3 (da) | 2000-09-18 |
DE69231333D1 (de) | 2000-09-14 |
FI933292A (fi) | 1993-07-21 |
NZ241357A (en) | 1994-04-27 |
NO932437D0 (no) | 1993-07-05 |
AU1339192A (en) | 1992-08-27 |
WO1992012994A1 (en) | 1992-08-06 |
JP3394534B2 (ja) | 2003-04-07 |
NO313241B1 (no) | 2002-09-02 |
US5709859A (en) | 1998-01-20 |
GR3034524T3 (en) | 2000-12-29 |
DE69231333T2 (de) | 2001-01-18 |
EP0568645A4 (en) | 1994-09-28 |
EP0568645A1 (en) | 1993-11-10 |
IL100731A0 (en) | 1992-09-06 |
CA2099779A1 (en) | 1992-07-25 |
ATE195254T1 (de) | 2000-08-15 |
AU648398B2 (en) | 1994-04-21 |
KR930703008A (ko) | 1993-11-29 |
FI933292A0 (fi) | 1993-07-21 |
IE920202A1 (en) | 1992-07-29 |
ES2148173T3 (es) | 2000-10-16 |
CA2099779C (en) | 2002-03-19 |
KR100259061B1 (ko) | 2000-07-01 |
EP0568645B1 (en) | 2000-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL100731A (en) | Mixed specificity fusion protein and pharmaceutical composition containing it | |
HU9602313D0 (en) | Antibody purification | |
AU1914795A (en) | Monoclonal antibodies specific to vegf receptors and uses thereof | |
PL330075A1 (en) | Antibodies against the ed-b domain of fibronectin, their construction and application | |
MY108519A (en) | Novel antibodies reactive with human carcinomas. | |
WO2001040307A8 (de) | Antikörper gegen signal-regulator-proteine | |
BR0314093A (pt) | Proteìnas de fusão de transferrina modificada-anticorpo | |
ES2149206T3 (es) | Purificacion de proteinas. | |
AU7272491A (en) | Tris-maleimido compounds as intermediates in trifunctional antibody synthesis | |
JPS6456697A (en) | Viii factor bonded domain of von willebrand's factor | |
EP1112085A4 (en) | ANTI-THROMBOTIC AGENT AND HUMANIZED MONOCLONAL ANTIBODY AGAINST VON-WILLEBRAND FACTOR | |
CA2171289A1 (en) | Il8 inhibitors | |
ATE217088T1 (de) | Bestimmung der endständigen sialinsäurereste des human-transferrin-moleküls | |
AU7390891A (en) | Anti-oncostatin m monoclonal antibodies | |
FR2708303B1 (fr) | Perfectionnement aux feuilles d'étanchéité en matériau bitumineux. | |
FR2710352B3 (fr) | Matériau complexe pour le renforcement de chaussées en bitume notamment. | |
FR2663641B1 (fr) | Composition de matiere pour empreintes. | |
IT1277143B1 (it) | Composizione di mescola per materiale d'attrito. | |
FI935159A0 (fi) | Laite rakeisen, jauheisen tai nestemäisen aineen tarkkaan levitykseen | |
ES1024652U (es) | Pelicula transparente para la formacion de contnenedores y/o de ventanillas de cajas de carton. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
RH | Patent void | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |